Capitainer Secures $5.7 Million to Advance Self-Sampling Tech

Capitainer has raised slightly more than $5.7 million to expand and commercialize its self-sampling technology for remote healthcare solutions and personalized medicine. The funding will be used to increase production capacity, develop new products, and intensify sales and marketing efforts. 

The investment round was led by Sciety and the network Sciety Venture Partners. “Thanks to the continued support from Sciety, we are able to accelerate our growth and expand our production capacity. Their expertise in life science combined with industry connections will be valuable for Capitainer as we continue to advance. We are confident that our self-sampling technology will become a game-changer in the healthcare industry, providing patients with greater convenience and accessibility while ensuring precise results,” Capitainer CEO Christopher Aulin said.
 
Capitainer’s self-sampling technology enables patients to take precise blood samples using a special card, which is then sent for analysis by standard postal services without the need for refrigeration or special packaging. Capitainer is experiencing growing demand for its products in several markets and has recently partnered with several distributors.
 
Capitainer is working to establish itself as the leading supplier of self-sampling solutions with market-leading clinical accuracy. The company’s rapid growth has attracted continued support from Sciety and its network Sciety Venture Partners, which have invested in Capitainer for the third time since 2019.
 
“We are excited to invest in Capitainer again and support their vision of revolutionizing blood sample collection. Capitainer’s innovative platform has the potential to significantly impact personalised medicine and remote healthcare, which is perfectly in line with Sciety’s vision to bring healthcare breakthroughs to people worldwide,” Sciety Managing Partner Andreas Lindblom stated.
 
Capitainer AB is a Swedish medtech company founded in 2016 that develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.